Thrombogenics CEO Discusses Product Pipeline Ahead of Catalyts, FDA Review
(Thomson Reuters ONE) -
In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF)
CEO Patrik De Haes discusses the company's pending FDA and EMA approvals of
ocriplasmin, a treatment for symptomatic vitreomacular adhesion. Current
procedures in the 500,000 patient market require a week-long recovery period in
which the patient remains immobilized face-down. Ocriplasmin, says De Haes, is
an outpatient treatment that requires one injection and no recovery time. Not
only is it faster, but De Haes says the injection may cost as little as $2000, a
fraction of the current $10,000 standard. He expects a late summer approval and
commercialization in the U.S. and Europe - with a helping hand from partner
Alcon, a division of Novartis (NYSE:NVS) - in Q1 of 2013.
De Haes also discusses results from studies of Thrombogenics' pipeline drug TB-
402, a post-surgery anticoagulant that has shown increased efficacy and similar
safety to Xarelto by Bayer (OTC:BAYRY), and Lovenox by Sanofi (NYSE:SNY).
To see the full video interview with Thrombogenics CEO Patrik De Haes, click
here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1625210]
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2012 - 13:45 Uhr
Sprache: Deutsch
News-ID 163298
Anzahl Zeichen: 2184
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 111 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thrombogenics CEO Discusses Product Pipeline Ahead of Catalyts, FDA Review"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
